Alf-Åge R. Pettersen
Position: MD, PhD
Phone: +4722117521/+4790535650
Email:

Project:ASCET-study(Aspirin non-responsiveness and Clopidogrel clinical Endpoint)

 

Author network for Alf-Åge R. Pettersen by COREMINE medical


Publications 2016

Opstad TB, Arnesen H, Pettersen AÅ, Seljeflot I (2016)
Combined Elevated Levels of the Proinflammatory Cytokines IL-18 and IL-12 Are Associated with Clinical Events in Patients with Coronary Artery Disease: An Observational Study
Metab Syndr Relat Disord, 14 (5), 242-8
PubMed 27058587

Opstad TB, Brusletto BS, Arnesen H, Pettersen AÅ, Seljeflot I (2016)
Cigarette smoking represses expression of cytokine IL-12 and its regulator miR-21-An observational study in patients with coronary artery disease
Immunobiology, 222 (2), 169-175
PubMed 27765464

Publications 2015

Pettersen AA, Arnesen H, Seljeflot I (2015)
A brief review on high on-aspirin residual platelet reactivity
Vascul Pharmacol, 67-69, 6-9
PubMed 25869498

Publications 2014

Opstad TB, Arnesen H, Pettersen AÅ, Seljeflot I (2014)
The MMP-9 -1562 C/T polymorphism in the presence of metabolic syndrome increases the risk of clinical events in patients with coronary artery disease
PLoS One, 9 (9), e106816
PubMed 25191702

Publications 2013

Opstad TB, Pettersen AÅ, Arnesen H, Seljeflot I (2013)
The co-existence of the IL-18+183 A/G and MMP-9 -1562 C/T polymorphisms is associated with clinical events in coronary artery disease patients
PLoS One, 8 (9), e74498
PubMed 24040261

Publications 2012

Bratseth V, Pettersen AÅ, Opstad TB, Arnesen H, Seljeflot I (2012)
Markers of hypercoagulability in CAD patients. Effects of single aspirin and clopidogrel treatment
Thromb J, 10 (1), 12
PubMed 22883224

Njerve IU, Pettersen AÅ, Opstad TB, Arnesen H, Seljeflot I (2012)
Fractalkine and its receptor (CX3CR1) in patients with stable coronary artery disease and diabetes mellitus
Metab Syndr Relat Disord, 10 (6), 400-6
PubMed 22897138

Pettersen AÅ, Arnesen H, Opstad TB, Bratseth V, Seljeflot I (2012)
Markers of endothelial and platelet activation are associated with high on-aspirin platelet reactivity in patients with stable coronary artery disease
Thromb Res, 130 (3), 424-8
PubMed 22795340

Pettersen AÅ, Seljeflot I, Abdelnoor M, Arnesen H (2012)
High On-Aspirin Platelet Reactivity and Clinical Outcome in Patients With Stable Coronary Artery Disease: Results From ASCET (Aspirin Nonresponsiveness and Clopidogrel Endpoint Trial)
J Am Heart Assoc, 1 (3), e000703
PubMed 23130135

Publications 2011

Opstad TB, Pettersen AÅ, Arnesen H, Seljeflot I (2011)
Circulating levels of IL-18 are significantly influenced by the IL-18 +183 A/G polymorphism in coronary artery disease patients with diabetes type 2 and the metabolic syndrome: an observational study
Cardiovasc Diabetol, 10, 110
PubMed 22141572

Opstad TB, Pettersen AA, Weiss TW, Akra S, Øvstebø R, Arnesen H, Seljeflot I (2011)
Genetic variation, gene-expression and circulating levels of matrix metalloproteinase-9 in patients with stable coronary artery disease
Clin Chim Acta, 413 (1-2), 113-20
PubMed 21963461

Pettersen AA, Arnesen H, Opstad TB, Seljeflot I (2011)
The influence of CYP 2C19*2 polymorphism on platelet function testing during single antiplatelet treatment with clopidogrel
Thromb J, 9, 4
PubMed 21426546

Publications 2010

Opstad TB, Pettersen AA, Bratseth V, Arnesen H, Seljeflot I (2010)
The influence of tissue factor and tissue factor pathway inhibitor polymorphisms on thrombin generation in stable coronary artery disease
Pathophysiol Haemost Thromb, 37 (2-4), 98-103
PubMed 21555871

Opstad TB, Pettersen AA, Weiss T, Arnesen H, Seljeflot I (2010)
Gender differences of polymorphisms in the TF and TFPI genes, as related to phenotypes in patients with coronary heart disease and type-2 diabetes
Thromb J, 8, 7
PubMed 20444258

Publications 2006

Solheim S, Pettersen AA, Arnesen H, Seljeflot I (2006)
No difference in the effects of clopidogrel and aspirin on inflammatory markers in patients with coronary heart disease
Thromb Haemost, 96 (5), 660-4
PubMed 17080224

Publications 2004

Pettersen AA, Müller C, Bendz B, Halvorsen S, Eritsland J, Brekke M, Mangschau A (2004)
[Reduction of myocardial infarction size after primary percutaneous coronary intervention]
Tidsskr Nor Laegeforen, 124 (10), 1387-9
PubMed 15195177

Pettersen AA, Seljeflot I, Abdelnoor M, Arnesen H (2004)
Unstable angina, stroke, myocardial infarction and death in aspirin non-responders. A prospective, randomized trial. The ASCET (ASpirin non-responsiveness and Clopidogrel Endpoint Trial) design
Scand Cardiovasc J, 38 (6), 353-6
PubMed 15804802